Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2022 AUA Annual Meeting
2022 Summit on Cancer Health Disparities
EHA2022 Congress
Digestive Disease Week 2022
2022 ASCO Annual Meeting
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Op-Ed
Advertisement
Advertisement
Jul
06
Today In Oncology
EAU22 New Research Supports Risk-Based Prostate Cancer Screening
Trastuzumab and Nivolumab Plus Either Ipilimumab or FOLFOX as First-Line Treatment for HER2-Positive Advanced Esophagogastric Adenocarcinoma
Lisocabtagene Maraleucel as Second-Line Treatment for Relapsed or Refractory Large B-Cell Lymphoma TRANSFORM Trial
Dual-Targeted Therapy Improves Outcomes vs Chemotherapy for Some Pediatric Patients With Low-Grade Glioma
EAU22 Study Finds Gut Microbes Differ in Patients With Prostate Cancer vs Those With Benign Biopsy Results
View More
Advertisement
